{
  "drug_name": "Oxacillin",
  "tradename": "Prostaphlin",
  "usage_and_dosing": {
    "general_info": [
      "Oxacillin is a semi-synthetic penicillinase-resistant penicillin used for parenteral therapy of infections due to methicillin-susceptible Staph. aureus (MSSA)."
    ],
    "adult_dose": "Usual dose: 1.5-2 gm IV q4h",
    "pediatric_dose": [
      {
        "age": ">28 Days",
        "dose": "150-200 mg/kg/day (divided q6h)"
      }
    ],
    "renal_adjustment": {
      "half_life_hrs_renal_function_normal": "0.5-0.7",
      "half_life_hrs_esrd": "No data",
      "dose_renal_function_normal": "2 gm IV q4h",
      "crcl_or_egfr": "Dosage recommendations not available",
      "hemodialysis": "No data",
      "capd": "No data",
      "crrt": "No data",
      "sled": "No data"
    },
    "hepatic_adjustment": {
      "note": "If concomitant renal and hepatic dysfunction, consider dosage reduction.",
      "mild_impairment_child_pugh_class_a": "No dosage adjustment",
      "moderate_impairment_child_pugh_class_b": "No dosage adjustment",
      "severe_impairment_child_pugh_class_c": "No dosage adjustment"
    },
    "other_adjustment": {
      "ecmo": "See ECMO Drug Dosing Adjustment."
    }
  },
  "adverse_effects": [
    "Hypersensitivity (rash [4%], anaphylaxis)",
    "Fever",
    "Local phlebitis",
    "Gastrointestinal: rare C. difficile infection",
    "Hematologic: positive Coombs (rare), neutropenia (rare), eosinophilia (22%), thrombocytopenia (rare)",
    "Hepatic dysfunction may occur with dose of ≥12 gm/day. LFTs usually increase 2-24 days after start of treatment, reversible.",
    "Acute interstitial nephritis (less than methicillin)",
    "In children, more rash and liver toxicity with Oxacillin as compared to Nafcillin (Clin Infect Dis 2002;34:50).",
    "Headache, confusion (rare)"
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "use_during_lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity."
  },
  "antimicrobial_spectrum": {
    "preferred": [
      "Staphylococcus aureus, methicillin-sensitive (MSSA)",
      "Staphylococcus epidermidis, methicillin-susceptible (MSSE)",
      "Staphylococcus lugdunensis",
      "Staphylococcus sp., coagulase-negative (Methicillin susceptible); S. hominis, S. capitis, others"
    ],
    "alternative": []
  },
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "pharmaceutical_preparations": "Injection",
    "peak_serum_conc_mcg_ml": "43 (500 mg IV, SD)",
    "protein_binding_percent": "90-94",
    "volume_of_distribution_vd": "0.4 L/kg",
    "avg_serum_t1_2_hr": "0.5-0.7",
    "elimination": "Renal",
    "bile_penetration_percent": 25,
    "csf_blood_percent": "10-15",
    "therapeutic_levels_in_csf": "Yes w/high doses"
  },
  "major_drug_interactions": [
    {
      "drug": "Probenecid",
      "effect_on_concentration": "↑ oxacillin",
      "suggested_management": "Monitor, adjust dosage"
    }
  ]
}